Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against DoubleVerify Holdings, Inc. due to allegations of misleading statements and failure to disclose critical information affecting investors [2][4]. Group 1: Allegations Against DoubleVerify - The complaint alleges that DoubleVerify's customers are shifting ad spending from open exchanges to closed platforms, where the company's technological capabilities are limited [4]. - It is claimed that DoubleVerify's ability to monetize its high-margin Activation Services is constrained due to the high costs and time required for technology development for closed platforms [4]. - The complaint states that DoubleVerify's competitors are better positioned to incorporate AI into their offerings, negatively impacting DoubleVerify's competitive edge and profitability [4]. - Allegations include that DoubleVerify systematically overbilled customers for ad impressions served to declared bots, and that risk disclosures were materially false and misleading [4]. Group 2: Impact of Disclosures - The truth about the alleged fraud was revealed through disclosures in February and March 2025, leading to a significant stock price drop of 36% following disappointing earnings [5]. - A report from Adalytics Research in March 2025 claimed that DoubleVerify's services were ineffective, further damaging investor confidence [5]. Group 3: Legal Proceedings - Investors who suffered losses in DoubleVerify are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options for participating in a federal securities class action [1][2]. - The deadline for seeking the role of lead plaintiff in the class action is set for July 21, 2025 [2].

Core Viewpoint - The Organon class action lawsuit alleges that the company and its executives made misleading statements regarding capital allocation and dividend payouts, leading to significant financial losses for investors [1][4]. Company Overview - Organon & Co. develops health solutions through prescription therapies and medical devices [3]. Allegations of the Lawsuit - The lawsuit claims that Organon concealed material information about its capital allocation priorities, particularly regarding the future of its quarterly dividend payout [4]. - It is alleged that Organon's reports on dividend payouts being a "number one priority" were misleading, as they were offset by a newly implemented debt reduction strategy, resulting in a more than 70% decrease in the quarterly dividend [4]. - The lawsuit also states that Organon intended to prioritize debt reduction following its acquisition of Dermavant Sciences Ltd [4]. Financial Impact - On May 1, 2025, Organon reported first quarter 2025 financial results, announcing a reduction in its dividend payout from $0.28 to $0.02, which led to a stock price decline of over 27% [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Organon securities during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ibotta, Inc. due to allegations of misleading statements and failure to disclose risks related to its contract with Kroger, which may have led to significant investor losses [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Ibotta to contact them to discuss legal options, particularly in light of a federal securities class action filed against the company [1][2]. - The deadline for investors to seek the role of lead plaintiff in the class action is June 16, 2025 [2]. Group 2: Financial Performance and Stock Impact - Ibotta conducted its IPO on April 13, 2024, offering 6.6 million shares at $88.00 each [5]. - The company reported a net loss of $34.0 million for Q2 2024, with operating expenses more than doubling year-over-year, leading to a 26% drop in stock price to $42.66 on August 14, 2024 [6]. - On February 26, 2025, Ibotta's stock fell 46% to $34.01 after reporting Q4 earnings that missed expectations and provided disappointing guidance for Q1 2025 [7]. Group 3: Contractual Risks - The complaint against Ibotta alleges that the company did not disclose the at-will nature of its contract with Kroger, which allowed Kroger to terminate the agreement without notice, posing a significant risk to investors [4].

Core Viewpoint - Becton, Dickinson and Company (BDX) has issued an urgent update regarding its esophagogastric balloon tamponade tubes due to safety concerns following one reported death and two serious injuries related to the device's use [1][2][4]. Company Update - The FDA has highlighted BD's updated instructions for the device, emphasizing potential hazards and the importance of proper usage procedures [2][6]. - BD has a market capitalization of $49.59 billion and an earnings yield of 8.1%, which is higher than the industry average of 5.3% [5]. Stock Performance - Following the announcement, BDX shares traded flat until Thursday's closing, with a year-to-date decline of 23.4%, compared to the industry's 0.8% decline and the S&P 500's 0.3% loss [3]. Safety Concerns - The FDA's safety communication was prompted by issues with the device during the pre-use phase, particularly difficulties in removing plastic plugs, which could damage the device [6][8]. - Complications from these issues could delay diagnosis or treatment, potentially worsening patient outcomes [8]. Response Measures - In response to the incidents, BD has communicated revised preparation steps to customers, including specific methods for safely removing plugs from the device [9][10]. - BD is reinforcing training across healthcare facilities and reviewing product handling instructions to enhance patient safety [10].

PHILADELPHIA, May 30, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) on behalf of purchasers of Viatris securities between August 8, 2024 through February 26, 2025, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired VIATRIS securities during the Class Period may, no later than JUNE 3, 2025, seek to be appointed as a lead plaintiff represent ...

SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, inclusive (the “Class Period”), have until July 28, 2025 to seek appointment as lead plaintiff of the UroGen class action lawsuit. Captioned Cockrell v. UroGen Pharma Ltd., 25-cv-06088 (D.N.J.), the UroGen class action lawsuit charges UroGen and certain of UroGen’s top current and former exe ...

Core Viewpoint - A class action has been filed against Canopy Growth Corporation for allegedly misleading investors regarding its cost reduction measures and financial performance during a specific period [1][2]. Allegations - The complaint alleges that Canopy Growth Corporation failed to disclose significant costs associated with the production of Claybourne pre-rolled joints and indirect costs related to Storz & Bickel vaporizer devices, which negatively impacted gross margins and overall financial results [2]. - It is claimed that the company overstated the effectiveness of its cost reduction measures while downplaying issues related to gross margins [2]. Financial Impact - On February 7, 2025, Canopy announced disappointing financial results attributed to the costs from the Claybourne product launch and increased indirect costs, leading to a 27.24% drop in share price, closing at $2.02 [3]. Class Action Participation - Shareholders may be eligible to participate in the class action against Canopy Growth Corporation, with a deadline to contact Robbins LLP by June 3, 2025, for those wishing to serve as lead plaintiff [4]. Company Background - Robbins LLP is noted for its focus on shareholder rights litigation, aiming to help shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Digimarc Corporation during the specified Class Period of the upcoming lead plaintiff deadline on July 8, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Digimarc securities between May 3, 2024, and February 26, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by July 8, 2025 [2]. - The lawsuit alleges that Digimarc made false and misleading statements regarding its business operations and revenue, which led to investor damages when the truth was revealed [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has been ranked highly for its performance in this area since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3].

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of Bakkt Holdings, Inc. related to misrepresentation of the company's financial stability and revenue sources [1][2]. Group 1: Allegations and Misrepresentation - Insiders at Bakkt allegedly caused the company to misrepresent or fail to disclose critical information regarding the stability and diversity of its crypto services revenue [2]. - It was revealed that Bakkt's crypto services revenue was heavily reliant on a single contract with Webull, raising concerns about revenue sustainability [2]. - The company's ability to maintain key client relationships was also questioned, suggesting that previous positive statements about Bakkt's business and prospects were misleading [2]. Group 2: Shareholder Actions - Shareholders who purchased BKKT shares prior to March 25, 2024, are encouraged to contact Kuehn Law to discuss potential legal actions, as there may be limited time to enforce their rights [3]. - Kuehn Law offers to cover all case costs and does not charge its investor clients, emphasizing the importance of shareholder involvement in maintaining market integrity [4].

NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Canopy Growth Corporation (NASDAQ: CGC) between May 30, 2024 and February 6, 2025, both dates inclusive (the "Class Period"), of the important June 3, 2025 lead plaintiff deadline. SO WHAT: If you purchased Canopy Growth securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem ...